Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.09+0.01 (+0.93%)
Close on Nov 13, 2026Market cap $4.82MP/E –Yield –
Skye Bioscience total assets
Total assets on the balance sheet at the end of each period.
Skye Bioscience's total assets was $5.07M at Sep 30, 2026. For fiscal 2025 it was $28.31M, down 61.1% from the year before. Over ten years it grew 23.2% a year on average. The highest annual figure on record is $72.76M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.31M | -61.1% |
| FY2024 | Dec 31, 2024 | $72.76M | +509.4% |
| FY2023 | Dec 31, 2023 | $11.94M | +31.1% |
| FY2022 | Dec 31, 2022 | $9.11M | -7.5% |
| FY2021 | Dec 31, 2021 | $9.86M | +268.9% |
| FY2020 | Dec 31, 2020 | $2.67M | +33.8% |
| FY2019 | Dec 31, 2019 | $2.00M | +2.0% |
| FY2018 | Dec 31, 2018 | $1.96M | +251.2% |
| FY2017 | Dec 31, 2017 | $557.22K | +72.3% |
| FY2016 | Dec 31, 2016 | $323.36K | -90.8% |
| FY2015 | Dec 31, 2015 | $3.51M | +2309.9% |
| FY2013 | Oct 31, 2013 | $145.69K | +239.7% |
| FY2012 | Oct 31, 2012 | $42.88K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.07M | -87.7% |
| Q2 FY2026 | Jun 30, 2026 | $11.03M | -78.8% |
| Q1 FY2026 | Mar 31, 2026 | $19.42M | -70.0% |
| Q4 FY2025 | Dec 31, 2025 | $28.31M | -61.1% |
| Q3 FY2025 | Sep 30, 2025 | $41.32M | -49.3% |
| Q2 FY2025 | Jun 30, 2025 | $52.16M | -40.2% |
| Q1 FY2025 | Mar 31, 2025 | $64.79M | -31.7% |
| Q4 FY2024 | Dec 31, 2024 | $72.76M | +509.4% |
| Q3 FY2024 | Sep 30, 2024 | $81.54M | +422.5% |
| Q2 FY2024 | Jun 30, 2024 | $87.26M | +3802.7% |
| Q1 FY2024 | Mar 31, 2024 | $94.84M | +1967.5% |
| Q4 FY2023 | Dec 31, 2023 | $11.94M | +31.1% |
| Q3 FY2023 | Sep 30, 2023 | $15.60M | +443.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.24M | -55.0% |
| Q1 FY2023 | Mar 31, 2023 | $4.59M | -36.4% |
| Q4 FY2022 | Dec 31, 2022 | $9.11M | -7.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.87M | -75.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.97M | -9.5% |
| Q1 FY2022 | Mar 31, 2022 | $7.21M | +33.6% |
| Q4 FY2021 | Dec 31, 2021 | $9.86M | +268.9% |
| Q3 FY2021 | Sep 30, 2021 | $11.69M | +168.7% |
| Q2 FY2021 | Jun 30, 2021 | $5.49M | +2315.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.40M | +702.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.67M | +33.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.35M | +152.1% |
| Q2 FY2020 | Jun 30, 2020 | $227.21K | -92.6% |
| Q1 FY2020 | Mar 31, 2020 | $672.98K | -85.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.00M | +2.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.73M | +48.0% |
| Q2 FY2019 | Jun 30, 2019 | $3.08M | +50.8% |
| Q1 FY2019 | Mar 31, 2019 | $4.72M | +49.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.96M | +251.2% |
| Q3 FY2018 | Sep 30, 2018 | $1.17M | +239.9% |
| Q2 FY2018 | Jun 30, 2018 | $2.04M | +321.9% |
| Q1 FY2018 | Mar 31, 2018 | $3.16M | +411.5% |
| Q4 FY2017 | Dec 31, 2017 | $557.22K | +72.3% |
| Q3 FY2017 | Sep 30, 2017 | $343.01K | – |
| Q2 FY2017 | Jun 30, 2017 | $484.05K | – |
| Q1 FY2017 | Mar 31, 2017 | $617.39K | – |
| Q4 FY2016 | Dec 31, 2016 | $323.36K | – |
See a number that looks wrong?